Suscribirse

Needleless connector decontamination for prevention of central venous access device infection: A pilot randomized controlled trial - 19/01/21

Doi : 10.1016/j.ajic.2020.07.026 
Claire M Rickard, PhD a, b, c, , Julie Flynn a, b, c, d, Emily Larsen, GDHealthRes a, b, c, Gabor Mihala, GCBiostats a, e, E Geoffrey Playford, PhD a, f, Joanie Shaw, GCCancerNurs g, Samantha Keogh, PhD a, c, d, Amanda Ullman, PhD a, b, c, h, Li Zhang, PhD a, i, Nicole Gavin, PhD a, c, d, Tricia Kleidon, MN (NursePractitioner) a, b, h, Vineet Chopra, MD a, j, Alexandra L. McCarthy, PhD a, k, Patricia Kuerten Rocha, PhD a, l, Nicole Marsh, PhD a, b, c
a Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia 
b School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia 
c Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia 
d School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland, Australia 
e School of Medicine, Griffith University, Nathan, Queensland, Australia 
f Infection Management Services, Princess Alexandra Hospital, Buranda, Queensland, Australia 
g Cancer, Immunology and Palliative Care, Gold Coast Health, Southport, Queensland, Australia 
h Queensland Children's Hospital, South Brisbane, Queensland, Australia 
i School of Dental Health Science, Griffith University, Gold Coast, Queensland, Australia 
j Internal Medicine, University of Michigan, Ann Arbor, MI 
k School of Nursing, University of Queensland, St Lucia, Queensland, Australia 
l Federal University of Santa Catarina, Florianopolis, SC, Brazil 

Address correspondence to Claire M Rickard, PhD, School of Nursing and Midwifery, Griffith University, 170 Kessels Road, Nathan 4111, Queensland, Australia.School of Nursing and MidwiferyGriffith University170 Kessels RoadNathanQueensland4111Australia

Highlights

Central venous access devices need physical and chemical ‘scrub the hub’ before use.
70% isopropyl alcohol wipes had 2% Central Line Associated Bloodstream Infection.
70% isopropyl alcohol caps had 2% Central Line Associated Bloodstream Infection.
Combined 70% isopropyl alcohol and 2% chlorhexidine gluconate wipe had no infection.
Large randomised controlled trials of cleaning methods are feasible and needed.

El texto completo de este artículo está disponible en PDF.

Resumen

Pilot randomized controlled trial (180 patients) of needleless connector decontamination. Central line-associated bloodstream infection occurred in 2% (1/61) of 70% isopropyl alcohol (IPA) wipe, 2% (1/59) of 70% IPA cap, and zero (0/58) infections in 2% chlorhexidine gluconate in 70% IPA wipe patients. Larger definitive trials are feasible and needed.

El texto completo de este artículo está disponible en PDF.

Key Words : Catheterization, Central venous, Catheter related infections, Chlorhexidine gluconate, Isopropyl alcohol, Infection control


Esquema


 Conflicts of Interest: C.M.R\220s employer, Griffith University, has received unrestricted investigator-initiated research grants on her behalf from (BD-Bard; Cardinal Health), and consultancy payments on her behalf from manufacturers (3M, BBraun, BD-Bard). E.L.\220s employer, Griffith University, has received on her behalf, an investigator-initiated grant from Cardinal Health (formerly Medtronic); E.L. has received an educational (conference) scholarship from Angiodynamics. S.K.\220s current employer (QUT) has received unrestricted educational grants on her behalf from product manufacturers (BD Medical). Griffith University (affiliated institution) has received consultancy payments on her behalf from manufacturers (BD Medical). A.J.U.\220s employer Griffith University has received unrestricted research grants and payments for educational lectures from 3M, Becton Dickinson [BD]-Bard, BBraun, and Cardinal Health on her behalf (unrelated to current project). T.M.K.\220s employer, Griffith University, has received funding on her behalf for investigator-initiated research or education grants from BD-Bard and Cardinal health; in addition to funding on her behalf for consultancy lectures or advice from 3M, Access Scientific, BD-Bard, Medical Specialties Australia and Vygon. V.C. has received grant support from the Agency for Healthcare Research and Quality and the American Hospital Association. He has also received royalties from Wolters Kluwer Health and Oxford University Press related to books he has authored. N.M.\220s previous employer Griffith University has received on her behalf investigator-initiated research grants from Becton Dickinson, and Cardinal Health and a consultancy payment provided to Griffith University from Becton Dickinson for clinical feedback all things (unrelated to the current project). No other conflicts to report.


© 2020  Association for Professionals in Infection Control and Epidemiology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 49 - N° 2

P. 269-273 - février 2021 Regresar al número
Artículo precedente Artículo precedente
  • Environmental detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from medical equipment in long-term care facilities undergoing COVID-19 outbreaks
  • Atiba Nelson, Jennifer Kassimatis, Jay Estoque, Cicely Yang, Geoff McKee, Elizabeth Bryce, Linda Hoang, Patricia Daly, Mark Lysyshyn, Althea S. Hayden, John Harding, Suni Boraston, Meena Dawar, Michael Schwandt
| Artículo siguiente Artículo siguiente
  • Safety code blue! Assessing the use of blue surgical sterilization wrap for homemade respirator masks during the COVID-19 crisis
  • Daniel T. Lammers, Ian F. Jones, Christopher W. Marenco, Kaitlin R. Morte, John M. McClellan, Matthew J. Eckert, Jason R. Bingham

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.